130 related articles for article (PubMed ID: 17146730)
1. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Kuppens IE; Witteveen PO; Schot M; Schuessler VM; Daehling A; Beijnen JH; Voest EE; Schellens JH
Invest New Drugs; 2007 Jun; 25(3):227-35. PubMed ID: 17146730
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.
Oostendorp RL; Witteveen PO; Schwartz B; Vainchtein LD; Schot M; Nol A; Rosing H; Beijnen JH; Voest EE; Schellens JH
Invest New Drugs; 2010 Apr; 28(2):163-70. PubMed ID: 19404582
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Shapiro GI; Kristeleit RS; Burris HA; LoRusso P; Patel MR; Drew Y; Giordano H; Maloney L; Watkins S; Goble S; Jaw-Tsai S; Xiao JJ
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):107-118. PubMed ID: 29799676
[TBL] [Abstract][Full Text] [Related]
4. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Wang-Gillam A; Arnold SM; Bukowski RM; Rothenberg ML; Cooper W; Wang KK; Gauthier E; Lockhart AC
Invest New Drugs; 2012 Feb; 30(1):266-72. PubMed ID: 20697774
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Ueda Y; Shimoyama T; Murakami H; Yamamoto N; Yamada Y; Arioka H; Tamura T
Cancer Chemother Pharmacol; 2011 May; 67(5):1101-9. PubMed ID: 20676675
[TBL] [Abstract][Full Text] [Related]
13. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
Kropff M; Kienast J; Bisping G; Berdel WE; Gaschler-Markefski B; Stopfer P; Stefanic M; Munzert G
Anticancer Res; 2009 Oct; 29(10):4233-8. PubMed ID: 19846979
[TBL] [Abstract][Full Text] [Related]
14. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Meek K; Goodwin A; Goodspeed W; Kromplewski M; Fouts ME; Medina D; Cho SY; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2006 Aug; 12(16):4882-7. PubMed ID: 16914576
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Zhu Y; Statkevich P; Cutler DL
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]